• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2020 年间质性肺病:进展历程。

Interstitial Lung Disease in 2020: A History of Progress.

机构信息

Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland Freiburgstrasse 18, 3010 Bern, Switzerland.

Respiratory Department, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW, 2050, Australia.

出版信息

Clin Chest Med. 2021 Jun;42(2):229-239. doi: 10.1016/j.ccm.2021.03.001.

DOI:10.1016/j.ccm.2021.03.001
PMID:34024399
Abstract

Interstitial lung diseases (ILDs) are heterogenous and complex chronic lung diseases that even today are challenging to diagnose and classify. The terminology and mechanistic understanding of specific ILDs have evolved substantially over the last centuries and decades, and clinicians, pathologists, radiologists, and researchers are continuously working to untangle the various ILDs of differing causes. Despite many drawbacks and negative clinical trials, the unremitting work of ILD researchers have resulted in great therapeutic successes over the last decade. In this chapter, the authors present historical aspects of ILD and build a foundation to understand current and emerging concepts in ILD.

摘要

间质性肺疾病(ILDs)是异质性和复杂的慢性肺部疾病,即使在今天,其诊断和分类仍然具有挑战性。几个世纪和几十年以来,ILD 的术语和发病机制的理解有了很大的发展,临床医生、病理学家、放射科医生和研究人员都在不断努力理清各种不同病因的ILD。尽管存在许多缺陷和负面临床试验,但ILD 研究人员的不懈努力在过去十年中取得了巨大的治疗成功。在本章中,作者介绍了ILD 的历史方面,并为理解ILD 的当前和新兴概念奠定了基础。

相似文献

1
Interstitial Lung Disease in 2020: A History of Progress.2020 年间质性肺病:进展历程。
Clin Chest Med. 2021 Jun;42(2):229-239. doi: 10.1016/j.ccm.2021.03.001.
2
Idiopathic interstitial pneumonitis/fibrosis: a historical note.特发性间质性肺炎/纤维化:历史回顾
Curr Opin Pulm Med. 1999 Sep;5(5):275-7. doi: 10.1097/00063198-199909000-00001.
3
Smoking-Related Interstitial Lung Disease: Historical Perspective and Advances in the Twenty-first Century.与吸烟相关的间质性肺疾病:二十一世纪的历史视角与进展。
Surg Pathol Clin. 2024 Jun;17(2):159-171. doi: 10.1016/j.path.2023.11.003. Epub 2023 Dec 7.
4
Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?特发性肺纤维化和与结缔组织病相关的间质性肺疾病中的循环肺生物标志物:我们处于什么位置?
Semin Arthritis Rheum. 2020 Jun;50(3):480-491. doi: 10.1016/j.semarthrit.2020.01.006. Epub 2020 Jan 28.
5
Interstitial lung diseases in the hospitalized patient.住院患者的间质性肺疾病
BMC Med. 2015 Sep 25;13:245. doi: 10.1186/s12916-015-0487-0.
6
Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.进行性纤维性间质性肺疾病:尼达尼布的新概念和适应证。
Mod Rheumatol. 2021 Jan;31(1):13-19. doi: 10.1080/14397595.2020.1826665.
7
Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.支气管肺泡灌洗术中胃蛋白酶与慢性纤维化间质性肺病预后的关系
Tohoku J Exp Med. 2018 Nov;246(3):147-153. doi: 10.1620/tjem.246.147.
8
The Role of Infection in Interstitial Lung Diseases: A Review.感染在间质性肺疾病中的作用:综述
Chest. 2017 Oct;152(4):842-852. doi: 10.1016/j.chest.2017.03.033. Epub 2017 Apr 8.
9
[Progress in the filed of pulmonary medicine in the last 100 years: Medical history of interstitial pneumonia].[过去100年肺部医学领域的进展:间质性肺炎病史]
Nihon Naika Gakkai Zasshi. 2002 Jun 10;91(6):1753-9.
10
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.尼达尼布治疗进行性肺纤维化间质性肺疾病患者- INBUILD 试验中按间质性肺疾病诊断的亚组分析:一项随机、双盲、安慰剂对照、平行组试验。
Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5.

引用本文的文献

1
Inequalities and age-period-cohort effects of global and regional burden for interstitial lung disease and pulmonary sarcoidosis: based on Global Burden of Disease study 2021.间质性肺疾病和结节病的全球及区域负担的不平等与年龄-时期-队列效应:基于《2021年全球疾病负担研究》
Front Med (Lausanne). 2025 May 26;12:1471402. doi: 10.3389/fmed.2025.1471402. eCollection 2025.
2
Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases.间质性肺疾病中慢性咳嗽的患病率、生活质量及管理的最新进展
Diagnostics (Basel). 2025 Apr 29;15(9):1139. doi: 10.3390/diagnostics15091139.
3
The global burden of heart failure attributable to interstitial lung diseases: insights from the global burden of disease study 2021.
间质性肺疾病所致心力衰竭的全球负担:来自《2021年全球疾病负担研究》的见解
BMC Cardiovasc Disord. 2025 Apr 7;25(1):262. doi: 10.1186/s12872-025-04702-y.
4
European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD).欧洲间质性肺疾病自我评估注册算法(eurILDreg ASA-ILD)
PLoS One. 2025 Jan 29;20(1):e0316484. doi: 10.1371/journal.pone.0316484. eCollection 2025.
5
Circulating MicroRNAs in Idiopathic Pulmonary Fibrosis: A Narrative Review.特发性肺纤维化中的循环微小RNA:一篇叙述性综述。
Curr Issues Mol Biol. 2024 Dec 4;46(12):13746-13766. doi: 10.3390/cimb46120821.
6
Protocol and research program of the European registry and biobank for interstitial lung diseases (eurILDreg).欧洲间质性肺病注册和生物库研究方案 (eurILDreg)。
BMC Pulm Med. 2024 Nov 18;24(1):572. doi: 10.1186/s12890-024-03389-9.
7
Multidisciplinary Approach to the Diagnosis of Idiopathic Interstitial Pneumonias: Focus on the Pathologist's Key Role.多学科方法诊断特发性间质性肺炎:关注病理学家的关键作用。
Int J Mol Sci. 2024 Mar 23;25(7):3618. doi: 10.3390/ijms25073618.
8
Quantification of fibrosis extend and airspace availability in lung: A semi-automatic ImageJ/Fiji toolbox.肺纤维化程度和空气空间可用性的量化:一种半自动的 ImageJ/Fiji 工具箱。
PLoS One. 2024 Feb 29;19(2):e0298015. doi: 10.1371/journal.pone.0298015. eCollection 2024.
9
Effect of noninvasive respiratory support on interstitial lung disease with acute respiratory failure: A systematic review and meta-analysis.无创呼吸支持对伴有急性呼吸衰竭的间质性肺疾病的影响:一项系统评价和荟萃分析。
Can J Respir Ther. 2023 Nov 3;59:232-244. doi: 10.29390/001c.89284. eCollection 2023.
10
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.曲妥珠单抗-德鲁替康(T-DXd)相关不良事件监测与管理的临床指导:来自亚太多学科专家组的见解。
Drug Saf. 2023 Oct;46(10):927-949. doi: 10.1007/s40264-023-01328-x. Epub 2023 Aug 8.